Nitazoxanide treatment for norovirus infection in solid organ transplant recipients

Norovirus (NV) is a major cause of acute gastroenteritis worldwide.1,2 In solid organ transplant (SOT) recipients, NV can lead to serious complications such as dehydration, malnutrition, renal dysfunction, and death.1,2 Previous case reports have described the use of immunosuppression reduction and immunoglobulins for treatment of NV in SOT recipients.1–4 Nitazoxanide is an antiprotozoal that is considered to have broad antiviral activity.5 Case series and reports have been published describing the use of nitazoxanide for the treatment of NV in immunocompromised hosts, though results are variable.1–4 We conducted this study to evaluate the effectiveness of nitazoxanide in adult and pediatric SOT recipients with NV.